Showing posts with label CBA. Show all posts
Showing posts with label CBA. Show all posts

Tuesday, April 07, 2009

Transform publishes comparative cost-effectiveness study of prohibition / regulation

Transform's latest report is published today:

A Comparison of the Cost-effectiveness of the Prohibition and Regulation of Drugs

media coverage listing below

Summary

‘The benefits of… [legalisation/regulation] – such as taxation, quality control and a reduction in the pressures on the criminal justice system – are far outweighed by the costs and for this reason, it is one that this Government will not pursue either domestically or internationally.”

Home Office Briefing, 2008

  • Despite the billions spent each year on proactive and reactive drug law enforcement, the punitive prohibitionist approach has consistently delivered the opposite of its stated goals. The Government’s own data clearly demonstrates drug supply and availability increasing; use of drugs that cause the most harm increasing; health harms increasing; massive levels of crime created at all scales leading to a crisis in the criminal justice system; and illicit drug profits enriching criminals, fuelling conflict and destabilising producer and transit countries from Mexico to Afghanistan. This is an expensive policy that, in the words of the UN Office on Drugs and Crime, has also created a raft of negative ‘unintended consequences’.

  • The UK Government specifically claims the benefits of any move away from prohibition towards legal regulation of drug markets would be outweighed by the costs. No such cost-benefit analysis, or even a proper Impact Assessment of existing enforcement policy and legislation has ever been carried out here or anywhere else in the world. Yet there are clear Government guidelines that an Impact Assessment should be triggered by amongst other things, a policy going out to public consultation or when ‘unintended consequences’ are identified, both of which have happened with drug policy in recent years.

  • Alternative approaches - involving established regulatory models of controlling drug production, supply and use - have not been considered or costed. The limited cost effectiveness analysis of current policy that has been undertaken has frequently been suppressed. In terms of scrutinizing major public policy and spending initiatives, current drug policy is unique in this regard.

  • The generalisations being used to defend continuation of an expensive and systematically failing policy of drugs prohibition, and close down a mature and rational exploration of alternative approaches, are demonstrably based on un-evidenced assumptions.

  • This paper is an attempt to begin to redress these failings by comparing the costs and benefits of the current policy of drug prohibition, with those of a proposed model for the legal regulation of drugs in the UK. We also identify areas of further research, and steps to ensure future drugs policy is genuinely based on evidence of what works.

  • This initial analysis demonstrates that a move to legally regulated drug supply would deliver substantial benefits to the Treasury and wider community, even in the highly unlikely event of a substantial increase in use.

Media Coverage:

BBC radio 4: The Today Programme:



New Statesman: Limping Along on the Left

Politics.co.uk: the cost of drug wars: £16 billion

Hungarian news portal:no translation available


not all the print coverage was positive / straight reportage:

South Wales Evening Post:
legalising drugs would lead to chaos

Daily Mail: Peter Hitchens: Eliot Ness couldn't stop booze, but he would win today's war on drugs ("Another parcel of garbage from the pro-drug lobby")


Other broadcast interviews included :

Radio:
  • BBC Five Live drive-time
  • BBC radio Wales
  • BBC radio London
  • Talk Sport radio
  • LBC radio
  • Liverpool city talk radio
  • SFM (South Africa national radio station)
TV
  • South Africa Broadcasting corporation TV news
  • BBC news channel
  • Channel five - The Wright Stuff (discussion of report not featuring Transform staff)



Wednesday, March 25, 2009

MP calls for impact assessment of drugs policy in Prime Minister’s Questions

In today’s Prime Minister’s Questions Lembit Opik MP requested a meeting with the PM to propose a full impact assessment of current drug policy.

His full question was:

“A new European Commission report on drugs shows that despite prohibition the illegal drugs trade has thrived, creating what the head of the UN Office on Drugs and Crime, Antonio Maria Costa, describes as a “staggering” criminal market, destabilising health policies and entire countries.


“As such, will the Leader of the House please convey my request to meet the Prime Minister to propose a comprehensive impact assessment of current drugs policy, to help us tackle this crisis in an evidence-based way?”

In response, Harriet Harman MP, Leader of the House, answering on behalf of the Prime Minister who is this week attending the G20 conference, said:

“I will pass on his request to the Prime Minister who I’m sure will agree that we need to make sure that every bit of support is available to those who are addicted to drugs and we need to crack down hard on dealers.”

UK drug enforcement policy is unique in terms of delivering the exact opposite of its intended outcomes, consistently, for decades - massive levels of drug misuse, health damage, and crime. This huge expenditure is also unique in the lack of scrutiny it has been subject to with regards to cost effectiveness or attempts to quantify these unintended negative consequences. Such scrutiny is long overdue and we welcome this initiative from Mr Opik

A full impact assessment laying out and counting the costs of current drugs policy in a structured and detailed way for the first time, would be a significant step towards making future policy evidence-based – and therefore more effective, just and humane.

Transform has long been calling for a full Cost Benefit of Analysis (CBA), which an impact assessment would be part of, comparing current UK drug policy with alternatives. We would like the UN to orchestrate a similar initiative at the global level. At a recent All Party Parliamentary Group on the Mis-use of Drugs meeting Transform laid down a challenge to all: support this approach, or don’t pretend you are interested in having evidence-based drugs policy.

We will be publishing our own UK oriented CBA soon, laying out the best evidence available, and the gaps in research that should be filled, so watch this space.